{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:43:11Z","timestamp":1788414191055,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cmi.2025.01.033","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:10:34Z","timestamp":1738408234000},"page":"761-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation"],"prefix":"10.1016","volume":"31","author":[{"given":"Tali","family":"Shafat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella J.","family":"Ariza-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyne","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.01.033_bib1","article-title":"Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives","volume":"206:115322","author":"Schalkwijk","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cmi.2025.01.033_bib2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/odi.14635","article-title":"Management of oral herpes simplex virus infections: the problem of resistance. A narrative review","volume":"30","author":"Piperi","year":"2024","journal-title":"Oral Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib3","doi-asserted-by":"crossref","first-page":"e2574","DOI":"10.1002\/rmv.2574","article-title":"Management of refractory\/resistant herpes simplex virus infections in haematopoietic stem cell transplantation recipients: a literature review","volume":"34","author":"Sall\u00e9e","year":"2024","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cmi.2025.01.033_bib4","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1128\/AAC.00977-15","article-title":"Sequence analysis of herpes simplex virus 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may be relevant for development of antiviral resistance","volume":"59","author":"Schmidt","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib5","doi-asserted-by":"crossref","first-page":"104421","DOI":"10.1016\/j.jcv.2020.104421","article-title":"Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients","volume":"128","author":"Anton-Vazquez","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2025.01.033_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2014.08.013","article-title":"Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France","volume":"111","author":"Frobert","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2025.01.033_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood.V99.3.1085","article-title":"Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation","volume":"99","author":"Langston","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2025.01.033_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.12227","article-title":"Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-case-control investigation","volume":"28","author":"Patel","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib10","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1086\/315524","article-title":"Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance","volume":"181","author":"Chakrabarti","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1086\/367894","article-title":"Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications","volume":"187","author":"Nichols","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/infdis\/jix042","article-title":"Association of the emergence of acyclovir-resistant herpes simplex virus type 1 with prognosis in hematopoietic stem cell transplantation patients","volume":"215","author":"Kakiuchi","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib13","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QCO.0000000000000889","article-title":"Resistant herpes simplex virus infections\u2014who, when, and what\u2019s new?","volume":"35","author":"Kotton","year":"2022","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/518938","article-title":"Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease","volume":"196","author":"Erard","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/tri.13142","article-title":"Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant\u2014a retrospective study","volume":"31","author":"Ariza-Heredia","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.cmi.2025.01.033_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000510988","article-title":"Topical treatment of acyclovir-resistant herpes simplex virus stomatitis after allogeneic hematopoietic cell transplantation","volume":"43","author":"Heidenreich","year":"2020","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.cmi.2025.01.033_bib17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1399-3046.2007.00822.x","article-title":"Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution","volume":"11","author":"Frangoul","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/pharmaceutics15010163","article-title":"Optimizing antiviral dosing for HSV and CMV treatment in immunocompromised patients","volume":"15","author":"Huntjens","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2025.01.033_bib19","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3390\/ijms23073431","article-title":"40 years after the registration of acyclovir: do we need new anti-herpetic drugs?","volume":"23","author":"Majewska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2025.01.033_bib20","doi-asserted-by":"crossref","first-page":"S622","DOI":"10.1093\/ofid\/ofab466.1254","article-title":"1060. Pritelivir in immunocompromised patients with mucocutaneous acyclovir-resistant herpes simplex virus-infections\u2014first case series","volume":"8","author":"Albrecht","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib21","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1021\/acs.jmedchem.2c00668","article-title":"Discovery, chemistry, and preclinical development of pritelivir, a novel treatment option for acyclovir-resistant herpes simplex virus infections","volume":"65","author":"Birkmann","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.cmi.2025.01.033_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1086\/315696","article-title":"Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients","volume":"182","author":"Morfin","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dkv285","article-title":"Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2","volume":"71","author":"Sauerbrei","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM199108223250805","article-title":"A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group","volume":"325","author":"Safrin","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.01.033_bib26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.01.033_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jgar.2019.05.004","article-title":"Herpes simplex virus resistant to acyclovir: a single-centre experience from the Czech Republic","volume":"19","author":"Fajfr","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.01.033_bib28","first-page":"ciae638","article-title":"Refractory and resistant herpes simplex virus mucocutaneous infections in immunocompromised patients: literature review and proposed definitions for use in clinical trials","author":"Chemaly","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcv.2017.10.002","article-title":"A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for herpes simplex virus (HSV) drug resistance testing","volume":"96","author":"Afshar","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2025.01.033_bib30","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00669-10","article-title":"Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals","volume":"54","author":"Burrel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib31","first-page":"1","volume":"58","author":"Mofenson","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2025.01.033_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European conference on infections in leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib33","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the national institutes of health, and the HIV medicine association of the infectious diseases society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2025.01.033_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13526","article-title":"AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2025.01.033_bib36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/ijsa.2010.010278","article-title":"European guideline for the management of genital herpes, 2010","volume":"22","author":"Patel","year":"2011","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2025.01.033_bib38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0956462417727194","article-title":"2017 European guidelines for the management of genital herpes","volume":"28","author":"Patel","year":"2017","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2025.01.033_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1399-3062.2006.00186.x","article-title":"Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient","volume":"9","author":"Andrei","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/sj.bmt.1702591","article-title":"Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant","volume":"26","author":"Blot","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1399-3062.2007.00261.x","article-title":"Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection","volume":"9","author":"Sims","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2010.06.020","article-title":"Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jiac.2018.07.004","article-title":"Improvement of refractory acyclovir-resistant herpes simplex virus type 1 infection by continuous acyclovir administration","volume":"25","author":"Ikawa","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-76-3-112-6-416","article-title":"Herpes simplex virus resistant to acyclovir. A study in a tertiary care center","volume":"112","author":"Englund","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.01.033_bib45","first-page":"3603","article-title":"Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir","volume":"24","author":"Epstein","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cmi.2025.01.033_bib46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/1078155214560921","article-title":"Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections","volume":"22","author":"Saunders","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cmi.2025.01.033_bib47","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1001\/archderm.147.12.1462","article-title":"Chronic acyclovir-resistant HSV-2 ulcer in an immunosuppressed patient treated with topical cidofovir","volume":"147","author":"Evans","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cmi.2025.01.033_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1078155212448408","article-title":"Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient","volume":"19","author":"Muluneh","year":"2013","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cmi.2025.01.033_bib49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/135965350400900107","article-title":"Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child","volume":"9","author":"Str\u00e1nsk\u00e1","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2025.01.033_bib50","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2022.01.010","article-title":"Acyclovir-resistant herpes simplex virus 1 keratitis: a concerning and emerging clinical challenge","volume":"238","author":"Rousseau","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2025.01.033_bib51","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/09564624211006568","article-title":"Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2","volume":"32","author":"Cannon","year":"2021","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2025.01.033_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01732-22","article-title":"Salvage treatment of refractory HSV oral lesions with pritelivir in allogeneic hematopoietic cell transplant recipients","volume":"67","author":"Bosetti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2444575","article-title":"Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database","author":"He","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2025.01.033_bib54","doi-asserted-by":"crossref","first-page":"ofae046","DOI":"10.1093\/ofid\/ofae046","article-title":"A multicenter assessment of the outcomes and toxicities of foscarnet for treatment of acyclovir-resistant mucocutaneous herpes simplex in immunocompromised patients","volume":"11","author":"Hammond","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/00006454-200111000-00016","article-title":"Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child","volume":"20","author":"Bryant","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2025.01.033_bib56","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/jac\/dkab259","article-title":"Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study","volume":"76","author":"Stern","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib57","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/516542","article-title":"A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS","volume":"176","author":"Lalezari","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib58","unstructured":"Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the centers for disease control and prevention, the national institutes of health, and the HIV medicine association of the infectious diseases society of America [Internet]. 2020. [Accessed at 02\/17\/2025]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/herpes-simplex?view=full."},{"key":"10.1016\/j.cmi.2025.01.033_bib59","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2165\/00003495-200767150-00006","article-title":"Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions","volume":"67","author":"Wagstaff","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2025.01.033_bib60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.abd.2020.10.019","article-title":"Acyclovir-resistant chronic mucocutaneous herpes with good response to the association with imiquimod in an AIDS patient: case report","volume":"97","author":"Oliveira","year":"2022","journal-title":"Bras Dermatol"},{"key":"10.1016\/j.cmi.2025.01.033_bib61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1473-3099(01)00095-0","article-title":"Topical immunomodulators\u2014progress towards treating inflammation, infection, and cancer","volume":"1","author":"Hengge","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-198223050-00001","article-title":"Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections","volume":"23","author":"Carmine","year":"1982","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2025.01.033_bib63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ICL.0000000000000952","article-title":"The impact of antiviral resistance on herpetic keratitis","volume":"49","author":"Moshirfar","year":"2023","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.cmi.2025.01.033_bib64","first-page":"CD002898","article-title":"Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis","volume":"1","author":"Wilhelmus","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2025.01.033_bib65","doi-asserted-by":"crossref","first-page":"592532","DOI":"10.1155\/2008\/592532","article-title":"Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy","volume":"2008","author":"Yudin","year":"2008","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.cmi.2025.01.033_bib66","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/v13071228","article-title":"Current drugs to treat infections with herpes simplex viruses-1 and -2","volume":"13","author":"Sadowski","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.01.033_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.drup.2010.11.002","article-title":"Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus","volume":"14","author":"Field","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cmi.2025.01.033_bib68","doi-asserted-by":"crossref","first-page":"105521","DOI":"10.1016\/j.antiviral.2022.105521","article-title":"Meeting report: 35th international conference on antiviral research in Seattle, Washington, USA\u2014March 21-25, 2022","volume":"211","author":"Spengler","year":"2023","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2025.01.033_bib69","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/jac\/dkac165","article-title":"Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients","volume":"77","author":"Serris","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.01.033_bib70","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.01.033_bib71","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial","volume":"316","author":"Wald","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.01.033_bib72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/1346-8138.16608","article-title":"A phase 3, randomized, double-blind, placebo-controlled study evaluating a single, patient-initiated dose of amenamevir for recurrent herpes labialis","volume":"50","author":"Kawashima","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.cmi.2025.01.033_bib73","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study","volume":"205","author":"Tyring","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib74","doi-asserted-by":"crossref","first-page":"ofac494","DOI":"10.1093\/ofid\/ofac494","article-title":"Single-dose, patient-initiated amenamevir therapy for recurrent genital herpes: a phase 3, randomized, double-blind, placebo-controlled study","volume":"9","author":"Kawashima","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib75","series-title":"Maruho receives manufacturing and marketing approval for a partial change of the indication and dosage\/administration for anti-herpes virus agent \u201cAmenalief Tab. 200 mg\u201d for the treatment of recurrent herpes simplex in Japan","year":"2023"},{"key":"10.1016\/j.cmi.2025.01.033_bib76","doi-asserted-by":"crossref","first-page":"107169","DOI":"10.1016\/j.ijantimicag.2024.107169","article-title":"Amenamevir for treating acyclovir-resistant or refractory herpes simplex virus infection in allogeneic hematopoietic stem cell transplantation recipients: two case reports","volume":"63","author":"Sall\u00e9e","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.01.033_bib77","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jha2.899","article-title":"Successful treatment of acyclovir-resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for T-cell prolymphocytic leukemia","volume":"5","author":"Kawamura","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.cmi.2025.01.033_bib78","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.08.024","article-title":"Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience","volume":"134","author":"El-Haddad","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2025.01.033_bib79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/tid.12582","article-title":"Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation","volume":"18","author":"Voigt","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.033_bib80","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2025.01.033_bib81","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25000412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25000412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:14:40Z","timestamp":1777641280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1198743X25000412"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.01.033","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}